Xintela AB Interim Report January - September 2024

MARKN.

Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.

The Group
Third quarter 2024
Income amounted to TSEK 2,822 (0).
Loss before tax totalled TSEK 8,049 (loss: 11,953).
Loss per share was SEK 0.01 (loss: 0.02).
 
First nine month 2024
Income amounted to TSEK 3,125 (0).
Loss before tax totalled TSEK 29,821 (loss: 46,192).
Loss per share was SEK 0.05 (loss: 0.11).
 
The Parent company
Third quarter 2024
Income amounted to TSEK 2,822 (0).
Loss before tax totalled TSEK 5,971 (loss: 8,916).
Loss per share was SEK 0.01 (loss: 0.02).
 
First nine month 2024
Income amounted to TSEK 3,125 (0).
Loss before tax totalled TSEK 24,225 (loss: 30,469).
Loss per share was SEK 0.04 (loss: 0.08).
At September 30, 2024, the equity/assets ratio was 31 % (82).
 
 
Significant events in the third quarter of 2024
* Xintela extends clinical study with XSTEM on knee osteoarthritis patients. (August 23, 2024)
* Xintela signs agreement with Region Östergötland for GMP process development of cell therapy for burn patients, (August 29, 2024)
* Xintela presents new preclinical data with the company's stem cell product XSTEM® on wound healing and skin regeneration at the International Society for Cell & Gene Therapy (ISCT) Europe 2024 conference, in Gothenburg. (September 5, 2024)
 
Significant events after the end of the period
* Xintela's main owner Flerie undertakes to exercise warrants TO3 of approximately SEK 28 million and provides bridging loans of SEK 9 million

The complete report is available for download below and on the company’s website www.xintela.se/en/report-archive.

Datum 2024-11-22, kl 08:15
Källa MFN
Bifogade filer
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!